EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone



Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone



Clinical Neuropharmacology 26(6): 297-298



Tardive dyskinesia is a potentially permanent and disfiguring side effect associated with the use of conventional, or first generation, antipsychotics. Quetiapine is a second generation antipsychotic with transient dopamine receptor occupancy, a property shared with clozapine. Quetiapine was administered to a patient who had persistent choreoathetoid movements that developed during treatment with conventional antipsychotics and remained unimproved during longterm treatment with risperidone. During 10 weeks of monotherapy with quetiapine, his Abnormal Involuntary Movement Scale score fell from 11 to 3. He was subsequently switched back to risperidone and his movements returned. The addition of quetiapine to his risperidone regimen once again resulted in a decrease of his tardive dyskinesia symptoms. The mechanism by which quetiapine improved tardive dyskinesia symptoms in this patient is not known, but differential treatment effects between the novel antipsychotics may exist. Controlled trials of quetiapine in the treatment of tardive dyskinesia should be pursued.

(PDF emailed within 0-6 h: $19.90)

Accession: 011731596

Download citation: RISBibTeXText

PMID: 14646608

DOI: 10.1097/00002826-200311000-00007



Related references

Chorea and tardive dyskinesia in a patient taking risperidone. Journal of Clinical Psychiatry 60(7): 485-487, 1999

Quetiapine treatment of risperidone-related tardive dyskinesia. A case report. Actas Espanolas de Psiquiatria 31(5): 306-306, 2003

Tardive dyskinesia in a patient treated with quetiapine. World Journal of Biological Psychiatry 10(1): 54-57, 2009

Tardive dyskinesia in an autistic patient treated with risperidone. American Journal of Psychiatry 161(4): 757-758, 2004

Clinical efficacy of risperidone in a patient with severe tardive dyskinesia. Schizophrenia Research 11(2): 194, 1994

Early-onset tardive dyskinesia in a neuroleptic-naive patient exposed to low-dose quetiapine. Movement Disorders 26(12): 2297-2298, 2012

Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine. International Clinical Psychopharmacology 15(1): 57-60, 2000

Late-onset Quetiapine-related Tardive Dyskinesia Side Effects in a Patient with Psychotic Depression. Clinical Psychopharmacology and Neuroscience 12(2): 163-165, 2014

Successful Management of Tardive Dyskinesia with Quetiapine and Clonazepam in a Patient of Schizophrenia with Type 2 Diabetes Mellitus. Clinical Psychopharmacology and Neuroscience 14(2): 218-220, 2016

Rapid remission of severe tardive dyskinesia and tardive dystonia with quetiapine. International Journal of Geriatric Psychiatry 20(3): 287-288, 2005

Development of tardive dyskinesia in a patient taking amisulpride. Progress in Neuro-Psychopharmacology & Biological Psychiatry 31(2): 586-587, 2007

Tardive dyskinesia in a patient taking haloperidol and fluoxetine. American Journal of Psychiatry 148(5): 683-683, 1991

Rapid onset tardive dyskinesia ("fly catcher tongue") in a neuroleptically naive patient induced by risperidone. Medicine and Health, Rhode Island 81(8): 271-272, 1998

Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology 15(1 Suppl 1): 36s-44s, 1995

Withdrawal-emergent dyskinesia in a patient taking risperidone/citalopram. Annals of PharmacoTherapy 34(2): 269-269, 2000